Nestlé Health Science (NHSc) is to acquire Aimmune Therapeutics in accordance with a definitive agreement between Nestlé and the biopharmaceutical company.
NHSc currently has a total investment in Aimmune of $473m, an approximate 25.6% equity ownership stake. The company made its initial investment of $145m in Aimmune in November 2016, followed by further investments of $30m in February 2018, $98m in November 2018 and $200m in January 2020.
